Christen said that if foods are going to be labeled GLP-1 Friendly, she hopes they are truly nutrient dense and come in reasonable portions
On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, citing no clinical need for large-scale compounding now that FDA-approved supply is stable
Back Finkelstein, EA, Trogdon, JG, Cohen, JW (2009) 'Annual medical spending attributable to obesity: payer-and service-specific estimates', Health Affairs , 28/5, w82231
Related solutions Grow your brand, now and through patent expiry Gain high value access and increase the profitability of your brands We empower life sciences with connected intelligence, transforming data into actionable insights for smarter decisions and better patient outcomes